title: pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment.
abstract: In the fight against cancer, controlled drug delivery systems have emerged to enhance the therapeutic efficacy and safety of anti-cancer drugs. Among these systems, mesoporous silica nanoparticles (MSNs) with a functional surface possess obvious advantages and were thus rapidly developed for cancer treatment. Many stimuli-responsive materials, such as nanoparticles, polymers, and inorganic materials, have been applied as caps and gatekeepers to control drug release from MSNs. This review presents an overview of the recent progress in the production of pH-responsive MSNs based on the pH gradient between normal tissues and the tumor microenvironment. Four main categories of gatekeepers can respond to acidic conditions. These categories will be described in detail.
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Ke-Ni
authors.initials: KN
authors.lastname: Yang
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Chun-Qiu
authors.initials: CQ
authors.lastname: Zhang
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Wang
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Zhou
authors.affiliation: 1 State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China ; 2 CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, China ; 3 Laboratory of Molecular Imaging, Department of Radiology, Howard University, Washington DC 20060, USA.
authors.forename: Xing-Jie
authors.initials: XJ
authors.lastname: Liang
keywords: Mesoporous silica nanoparticles; antineoplastic protocols; controlled drug release; drug delivery systems; pH-responsive
references.citation: Exp Biol Med (Maywood). 2009 Feb;234(2):123-31
references.pmid: 19064945
references.citation: J Control Release. 2003 Jan 9;86(1):33-48
references.pmid: 12490371
references.citation: Biochem Pharmacol. 1992 Aug 4;44(3):509-17
references.pmid: 1354963
references.citation: J Mater Chem B. 2013 Mar 21;1(11):1644-1648
references.pmid: 32260728
references.citation: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references.pmid: 18758474
references.citation: Eur J Pharm Biopharm. 2009 Mar;71(3):431-44
references.pmid: 18977297
references.citation: J Control Release. 2010 Dec 1;148(2):135-46
references.pmid: 20797419
references.citation: J Am Chem Soc. 2010 Feb 10;132(5):1500-1
references.pmid: 20085351
references.citation: Eur J Pharm Sci. 2009 Oct 8;38(3):185-96
references.pmid: 19646528
references.citation: Nanotechnology. 2012 Jun 15;23(23):235605
references.pmid: 22595678
references.citation: Biomaterials. 2010 Oct;31(30):7797-804
references.pmid: 20673684
references.citation: ACS Nano. 2009 Jan 27;3(1):16-20
references.pmid: 19206243
references.citation: Adv Mater. 2012 Mar 22;24(12):1504-34
references.pmid: 22378538
references.citation: Chem Commun (Camb). 2012 Aug 7;48(61):7542-52
references.pmid: 22737687
references.citation: Angew Chem Int Ed Engl. 2010 Oct 25;49(44):8214-9
references.pmid: 20865709
references.citation: Chem Soc Rev. 2012 May 7;41(9):3679-98
references.pmid: 22441299
references.citation: Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
references.pmid: 12204596
references.citation: Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):406-12
references.pmid: 23816639
references.citation: Adv Mater. 2012 Dec 18;24(48):6433-7
references.pmid: 23001882
references.citation: Int J Pharm. 2011 Dec 15;421(2):388-96
references.pmid: 22001840
references.citation: Trends Pharmacol Sci. 2009 Nov;30(11):592-9
references.pmid: 19837467
references.citation: Integr Biol (Camb). 2013 Jan;5(1):96-107
references.pmid: 22869005
references.citation: Nat Mater. 2013 Nov;12(11):991-1003
references.pmid: 24150417
references.citation: J Am Chem Soc. 2009 Sep 16;131(36):12912-4
references.pmid: 19705840
references.citation: J Am Chem Soc. 2011 Jun 15;133(23):8778-81
references.pmid: 21574653
references.citation: Adv Drug Deliv Rev. 2008 Aug 17;60(11):1307-1315
references.pmid: 18555555
references.citation: Angew Chem Int Ed Engl. 2011 Sep 12;50(38):8853-7
references.pmid: 21826770
references.citation: J Am Chem Soc. 2010 Sep 15;132(36):12690-7
references.pmid: 20718462
references.citation: J Mater Chem B. 2013 Nov 21;1(43):5886-5898
references.pmid: 32261055
references.citation: Adv Drug Deliv Rev. 2008 Dec 14;60(15):1650-62
references.pmid: 18848591
references.citation: Chem Asian J. 2014 Jan;9(1):319-27
references.pmid: 24115568
references.citation: Adv Enzyme Regul. 2001;41:189-207
references.pmid: 11384745
references.citation: Eur J Pharm Biopharm. 2013 May;84(1):91-8
references.pmid: 23207322
references.citation: Expert Opin Drug Deliv. 2010 Mar;7(3):307-19
references.pmid: 20095875
references.citation: Acta Biomater. 2008 Jul;4(4):1024-37
references.pmid: 18329348
references.citation: Chem Soc Rev. 2012 Apr 7;41(7):2590-605
references.pmid: 22216418
references.citation: Macromol Biosci. 2012 Feb;12(2):251-9
references.pmid: 22076739
references.citation: Langmuir. 2011 Mar 15;27(6):3095-9
references.pmid: 21314163
references.citation: Int J Pharm. 2013 Jun 25;450(1-2):296-303
references.pmid: 23598077
references.citation: Nanomedicine. 2014 Jan;10(1):19-34
references.pmid: 23871761
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1310-6
references.pmid: 18316549
references.citation: Prog Lipid Res. 2005 Jan;44(1):68-97
references.pmid: 15748655
references.citation: J Am Chem Soc. 2009 Apr 8;131(13):4783-7
references.pmid: 19173646